Filter

Refine by collections

Refine by date

—
  • Print
  • Save

Search Results

You are looking at 1 - 10 of 21 items for :

Clear All
Anna Eremkina Endocrinology Research Center, Russian Federation, Moscow, Russia

Search for other papers by Anna Eremkina in
Google Scholar
PubMed Close
,
Julia Krupinova Endocrinology Research Center, Russian Federation, Moscow, Russia

Search for other papers by Julia Krupinova in
Google Scholar
PubMed Close
,
Ekaterina Dobreva Endocrinology Research Center, Russian Federation, Moscow, Russia

Search for other papers by Ekaterina Dobreva in
Google Scholar
PubMed Close
,
Anna Gorbacheva Endocrinology Research Center, Russian Federation, Moscow, Russia

Search for other papers by Anna Gorbacheva in
Google Scholar
PubMed Close
,
Ekaterina Bibik Endocrinology Research Center, Russian Federation, Moscow, Russia

Search for other papers by Ekaterina Bibik in
Google Scholar
PubMed Close
,
Margarita Samsonova Faculty of Fundamental Medicine, ederal State Budget Educational Institution of Higher Education M.V. Lomonosov Moscow State University, Moscow, Russia

Search for other papers by Margarita Samsonova in
Google Scholar
PubMed Close
,
Alina Ajnetdinova Endocrinology Research Center, Russian Federation, Moscow, Russia

Search for other papers by Alina Ajnetdinova in
Google Scholar
PubMed Close
, and
Natalya Mokrysheva Endocrinology Research Center, Russian Federation, Moscow, Russia

Search for other papers by Natalya Mokrysheva in
Google Scholar
PubMed Close

( 6 , 7 ). The data on the efficacy and safety of denosumab led to its approval for postmenopausal osteoporosis, skeletal complications and hypercalcemia of malignancies. In case of postmenopausal osteoporosis denosumab reduces the risk of vertebral

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-20-0380
Volume/Issue:
Volume 9: Issue 10
Open access
Athanasios D Anastasilakis Department of Endocrinology, 424 General Military Hospital, Thessaloniki, Greece

Search for other papers by Athanasios D Anastasilakis in
Google Scholar
PubMed Close
,
Marina Tsoli 1st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Marina Tsoli in
Google Scholar
PubMed Close
,
Gregory Kaltsas 1st Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed Close
, and
Polyzois Makras Department of Endocrinology and Diabetes, 251 Hellenic Air Force & VA General Hospital, Athens, Greece

Search for other papers by Polyzois Makras in
Google Scholar
PubMed Close

effects have been reported in patients with LCH treated with bisphosphonates ( 60 ). Novel treatment approaches Denosumab, an antibody targeting RANKL, has been used as a treatment in osteoporosis and has recently been approved for diminishing the

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-18-0186
Volume/Issue:
Volume 7: Issue 7
Open access
Herjan J T Coelingh Bennink Pantarhei Oncology, Zeist, The Netherlands

Search for other papers by Herjan J T Coelingh Bennink in
Google Scholar
PubMed Close
,
Jan Krijgh Pantarhei Oncology, Zeist, The Netherlands

Search for other papers by Jan Krijgh in
Google Scholar
PubMed Close
,
Jan F M Egberts Terminal 4 Communications, Hilversum, The Netherlands

Search for other papers by Jan F M Egberts in
Google Scholar
PubMed Close
,
Maria Slootweg Independent Consultant, Zeist, The Netherlands

Search for other papers by Maria Slootweg in
Google Scholar
PubMed Close
,
Harm H E van Melick Department of Urology, St. Antonius Hospital, Nieuwegein, The Netherlands

Search for other papers by Harm H E van Melick in
Google Scholar
PubMed Close
,
Erik P M Roos Department of Urology, Antonius Hospital, Sneek, The Netherlands

Search for other papers by Erik P M Roos in
Google Scholar
PubMed Close
,
Diederik M Somford Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands

Search for other papers by Diederik M Somford in
Google Scholar
PubMed Close
,
Yvette Zimmerman Pantarhei Oncology, Zeist, The Netherlands

Search for other papers by Yvette Zimmerman in
Google Scholar
PubMed Close
,
Iman J Schultz Pantarhei Oncology, Zeist, The Netherlands

Search for other papers by Iman J Schultz in
Google Scholar
PubMed Close
,
Noel W Clarke The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK

Search for other papers by Noel W Clarke in
Google Scholar
PubMed Close
,
R Jeroen A van Moorselaar Department of Urology, Amsterdam UMC, VU University, Amsterdam, The Netherlands

Search for other papers by R Jeroen A van Moorselaar in
Google Scholar
PubMed Close
, and
Frans M J Debruyne Andros Clinics, Arnhem, The Netherlands

Search for other papers by Frans M J Debruyne in
Google Scholar
PubMed Close

are bisphosphonates, denosumab or selective estrogen receptor modulators (SERMs) ( 13 ). However, these compounds may have side effects. Both short-term (e.g. hypocalcemia or ocular inflammation) and long-term (e.g. osteonecrosis or atrial fibrillation

Article Type:
Review Article
Collections:
Bone and Mineral Metabolism
DOI:
https://doi.org/10.1530/EC-22-0182
Volume/Issue:
Volume 11: Issue 12
Open access
Katherine Van Loon
Search for other papers by Katherine Van Loon in
Google Scholar
PubMed Close
,
Li Zhang
Search for other papers by Li Zhang in
Google Scholar
PubMed Close
,
Jennifer Keiser
Search for other papers by Jennifer Keiser in
Google Scholar
PubMed Close
,
Cendy Carrasco
Search for other papers by Cendy Carrasco in
Google Scholar
PubMed Close
,
Katherine Glass The UCSF Helen Diller Family Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network, University of California, San Francisco, 1600 Divisadero Street, UCSF Box 1770, San Francisco, California 94143, USA

Search for other papers by Katherine Glass in
Google Scholar
PubMed Close
,
Maria-Teresa Ramirez The UCSF Helen Diller Family Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network, University of California, San Francisco, 1600 Divisadero Street, UCSF Box 1770, San Francisco, California 94143, USA

Search for other papers by Maria-Teresa Ramirez in
Google Scholar
PubMed Close
,
Sarah Bobiak The UCSF Helen Diller Family Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network, University of California, San Francisco, 1600 Divisadero Street, UCSF Box 1770, San Francisco, California 94143, USA

Search for other papers by Sarah Bobiak in
Google Scholar
PubMed Close
,
Eric K Nakakura
Search for other papers by Eric K Nakakura in
Google Scholar
PubMed Close
,
Alan P Venook
Search for other papers by Alan P Venook in
Google Scholar
PubMed Close
,
Manisha H Shah The UCSF Helen Diller Family Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network, University of California, San Francisco, 1600 Divisadero Street, UCSF Box 1770, San Francisco, California 94143, USA

Search for other papers by Manisha H Shah in
Google Scholar
PubMed Close
, and
Emily K Bergsland
Search for other papers by Emily K Bergsland in
Google Scholar
PubMed Close

form of bone-directed therapy: 50% received a form of radiation, 45% received a bisphosphonate, 18% underwent surgical resection, 13% received 131 I-MIBG, and 5% received denosumab. Moreover, 46% were treated with more than one treatment modality

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-14-0119
Volume/Issue:
Volume 4: Issue 1
Open access
Sondra O’Callaghan Endocrinology, Diabetes & Metabolism, Orlando VA Healthcare System, Orlando, Florida, USA

Search for other papers by Sondra O’Callaghan in
Google Scholar
PubMed Close
and
Hanford Yau Endocrinology, Diabetes & Metabolism, Orlando VA Healthcare System, Orlando, Florida, USA

Search for other papers by Hanford Yau in
Google Scholar
PubMed Close

reduction is temporary. Denosumab came to market in 2010 as the first novel agent in 30 years targeted at inhibiting bone resorption. It is a human MAB that binds to and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), the primary

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-20-0487
Volume/Issue:
Volume 10: Issue 1
Open access
Martine Cohen-Solal Department of Skeletal Diseases, INSERM U1132 & Université de Paris, Hôpital Lariboisière, Paris, France

Search for other papers by Martine Cohen-Solal in
Google Scholar
PubMed Close
,
Thomas Funck-Brentano Department of Skeletal Diseases, INSERM U1132 & Université de Paris, Hôpital Lariboisière, Paris, France

Search for other papers by Thomas Funck-Brentano in
Google Scholar
PubMed Close
, and
Pablo Ureña Torres AURA Nord, Saint Ouen, France
Department of Renal Physiology, Necker Hospital, Université de Paris, Paris, France

Search for other papers by Pablo Ureña Torres in
Google Scholar
PubMed Close

treatment of CKD stage 4–5D patients with osteoporosis, that is, low bone mass or fractures remained a challenge. A more recent drug offered new opportunities. Denosumab at the dose of 60 mg prescribed for the prevention of fracture in patients at high risk

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-20-0039
Volume/Issue:
Volume 9: Issue 4
Open access
Jennifer Walsh The Mellanby Centre for Bone Research, The Medical School, The University of Sheffield, Sheffield, UK

Search for other papers by Jennifer Walsh in
Google Scholar
PubMed Close
,
Neil Gittoes Centre for Endocrinology, Diabetes and Metabolism, University Hospitals Birmingham & University of Birmingham, Birmingham Health Partners, Birmingham, UK

Search for other papers by Neil Gittoes in
Google Scholar
PubMed Close
,
Peter Selby Department of Medicine, Manchester Royal Infirmary, Manchester, UK

Search for other papers by Peter Selby in
Google Scholar
PubMed Close
, and
the Society for Endocrinology Clinical Committee The Society for Endocrinology, 22 Apex Court, Woodlands, Bradley Stoke, Bristol, UK

Search for other papers by the Society for Endocrinology Clinical Committee in
Google Scholar
PubMed Close

Calcimimetics, denosumab, calcitonin Under specialist supervision Can be considered if poor response to other measures Parathyroidectomy Can be considered in acute presentation of primary hyperparathyroidism if severe hypercalcaemia and poor

Article Type:
Other
DOI:
https://doi.org/10.1530/EC-16-0055
Volume/Issue:
Volume 5: Issue 5
Open access
Matteo Scopel Medical Clinic III, Department of Medicine (DIMED), University Hospital of Padua, Padua, Italy

Search for other papers by Matteo Scopel in
Google Scholar
PubMed Close
,
Eugenio De Carlo Medical Clinic III, Department of Medicine (DIMED), University Hospital of Padua, Padua, Italy

Search for other papers by Eugenio De Carlo in
Google Scholar
PubMed Close
,
Francesca Bergamo Unit of Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

Search for other papers by Francesca Bergamo in
Google Scholar
PubMed Close
,
Sabina Murgioni Unit of Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

Search for other papers by Sabina Murgioni in
Google Scholar
PubMed Close
,
Riccardo Carandina Radiodiagnostic Unit, University Hospital of Padua, Padua, Italy

Search for other papers by Riccardo Carandina in
Google Scholar
PubMed Close
,
Anna Rita Cervino Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy

Search for other papers by Anna Rita Cervino in
Google Scholar
PubMed Close
,
Marta Burei Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy

Search for other papers by Marta Burei in
Google Scholar
PubMed Close
,
Federica Vianello Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy

Search for other papers by Federica Vianello in
Google Scholar
PubMed Close
,
Vittorina Zagonel Unit of Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

Search for other papers by Vittorina Zagonel in
Google Scholar
PubMed Close
,
Matteo Fassan Surgical Pathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy

Search for other papers by Matteo Fassan in
Google Scholar
PubMed Close
, and
Roberto Vettor Medical Clinic III, Department of Medicine (DIMED), University Hospital of Padua, Padua, Italy

Search for other papers by Roberto Vettor in
Google Scholar
PubMed Close

, both alone and in association with local radiotherapy (23% in synchronous and 24% in metachronous). In our series, few patients are treated with denosumab or orthopedic corset (data not shown). The skeletal-related events (pathological fractures or

Article Type:
Research Article
Collections:
Hormones and Cancer
DOI:
https://doi.org/10.1530/EC-21-0568
Volume/Issue:
Volume 11: Issue 7
Open access
Ann-Kristin Picke Institute of Comparative Molecular Endocrinology, Ulm University, Ulm, Germany

Search for other papers by Ann-Kristin Picke in
Google Scholar
PubMed Close
,
Graeme Campbell Institute of Biomechanics, TUHH Hamburg University of Technology, Hamburg, Germany

Search for other papers by Graeme Campbell in
Google Scholar
PubMed Close
,
Nicola Napoli Diabetes and Bone Network, Department Endocrinology and Diabetes, University Campus Bio-Medico of Rome, Rome, Italy
Division of Bone and Mineral Diseases, Washington University in St Louis, St Louis, Missouri, USA

Search for other papers by Nicola Napoli in
Google Scholar
PubMed Close
,
Lorenz C Hofbauer Department of Medicine III & Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany

Search for other papers by Lorenz C Hofbauer in
Google Scholar
PubMed Close
, and
Martina Rauner Department of Medicine III & Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany

Search for other papers by Martina Rauner in
Google Scholar
PubMed Close

regarding non-vertebral fractures (reviewed in 176 ). Thus, even though bisphosphonate further suppress bone turnover, they may still be an effective therapy for patients with T2DM. Denosumab Denosumab is a monoclonal antibody targeted against RANKL

Article Type:
Review Article
DOI:
https://doi.org/10.1530/EC-18-0456
Volume/Issue:
Volume 8: Issue 3
Open access
Cheng Han Ng Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Search for other papers by Cheng Han Ng in
Google Scholar
PubMed Close
,
Yip Han Chin Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Search for other papers by Yip Han Chin in
Google Scholar
PubMed Close
,
Marcus Hon Qin Tan Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Search for other papers by Marcus Hon Qin Tan in
Google Scholar
PubMed Close
,
Jun Xuan Ng Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Search for other papers by Jun Xuan Ng in
Google Scholar
PubMed Close
,
Samantha Peiling Yang Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Department of Medicine, National University Hospital, Singapore

Search for other papers by Samantha Peiling Yang in
Google Scholar
PubMed Close
,
Jolene Jiayu Kiew Department of Medicine, National University Hospital, Singapore

Search for other papers by Jolene Jiayu Kiew in
Google Scholar
PubMed Close
, and
Chin Meng Khoo Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Department of Medicine, National University Hospital, Singapore

Search for other papers by Chin Meng Khoo in
Google Scholar
PubMed Close

dose was 43.4 mg with most patients maintained at 25–50 mg per day. Twenty-six with bisphosphonates, denosumab or estrogen receptor modulators 6 Koman et al . 2019 Retrospective 101/110 62 PHPT Patients were started with 30 mg of

Article Type:
Research Article
DOI:
https://doi.org/10.1530/EC-20-0221
Volume/Issue:
Volume 9: Issue 7
Open access